Drugs, Drugs Industry | featured news

J&J agreed to buy an 18.4% stake in Elan for $1 billion and acquire the rights to much of the Irish biotech company's research into drugs for Alzheimer's disease.

One of the drug industry's most renowned names is having a lot of trouble landing new drugs.

Deal talks between Genentech and Roche hit a snag over dueling interpretations of arcane SEC rules, but the problem is unlikely to derail the transaction, according to people familiar with the matter.

Dow Chemical and Rohm & Haas have reached a tentative deal to complete their disputed $15 billion merger, according to people briefed on the situation.

Drugmakers Merck & Co. and Schering-Plough Corp. are planning to merge under the name Merck in a stock-and-cash deal worth about $41.1 billion.

Swiss drug company Roche Holding increased its offer to acquire the rest of Genentech to $93 a share from $86.50.

Walgreen Co. executives are considering selling booze at its drugstores after phasing out beer and wine at all but a few hundred stores in the 1990s.

Justices said a drug company is not protected from injury claims merely because the federal government had approved the products and labeling.

Pfizer Inc. reportedly is close to an agreement to acquire rival drug maker Wyeth for between $65 billion and $70 billion in a cash-and-stock deal that could be announced as early as next week,